133 related articles for article (PubMed ID: 12449148)
21. Anti-tumor activity of pamidronate in human multiple myeloma.
Kondo H; Mori A
Leuk Lymphoma; 2002 Apr; 43(4):919-21. PubMed ID: 12153188
[TBL] [Abstract][Full Text] [Related]
22. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
Dranitsaris G
Int J Technol Assess Health Care; 1999; 15(1):108-22. PubMed ID: 10407599
[TBL] [Abstract][Full Text] [Related]
23. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
Theriault RL; Lipton A; Hortobagyi GN; Leff R; Glück S; Stewart JF; Costello S; Kennedy I; Simeone J; Seaman JJ; Knight RD; Mellars K; Heffernan M; Reitsma DJ
J Clin Oncol; 1999 Mar; 17(3):846-54. PubMed ID: 10071275
[TBL] [Abstract][Full Text] [Related]
24. Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
Br J Haematol; 1998 Nov; 103(2):530-2. PubMed ID: 9827929
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
26. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.
D'Arena G; Gobbi PG; Broglia C; Sacchi S; Quarta G; Baldini L; Iannitto E; Falcone A; Guariglia R; Pietrantuono G; Villani O; Martorelli MC; Mansueto G; Sanpaolo G; Cascavilla N; Musto P; ; ;
Leuk Lymphoma; 2011 May; 52(5):771-5. PubMed ID: 21299465
[TBL] [Abstract][Full Text] [Related]
27. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Brincker H; Westin J; Abildgaard N; Gimsing P; Turesson I; Hedenus M; Ford J; Kandra A
Br J Haematol; 1998 May; 101(2):280-6. PubMed ID: 9609523
[TBL] [Abstract][Full Text] [Related]
28. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk].
Díaz C; Soutelo MJ; Quiroga L; Palmer L; Lutfi R
Medicina (B Aires); 2004; 64(4):289-94. PubMed ID: 15338969
[TBL] [Abstract][Full Text] [Related]
30. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
[TBL] [Abstract][Full Text] [Related]
31. Myeloma--the therapeutic challenge.
Berenson JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():19-21. PubMed ID: 11089383
[TBL] [Abstract][Full Text] [Related]
32. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
33. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Bloomfield DJ
J Clin Oncol; 1998 Mar; 16(3):1218-25. PubMed ID: 9508210
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
35. Pamidronate disodium reduces skeletal complications of multiple myeloma.
Oncology (Williston Park); 1996 Feb; 10(2):253. PubMed ID: 8838269
[No Abstract] [Full Text] [Related]
36. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates in clinical oncology. The development of pamidronate.
Thürlmann B
Recent Results Cancer Res; 1999; 149():1-113. PubMed ID: 10087580
[No Abstract] [Full Text] [Related]
38. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs M; Blacklock H; Bell R; Simeone JF; Reitsma DJ; Heffernan M; Seaman J; Knight RD
J Clin Oncol; 1998 Feb; 16(2):593-602. PubMed ID: 9469347
[TBL] [Abstract][Full Text] [Related]
39. Effect of calcitriol and pamidronate in multiple myeloma.
Imseis RE; Palmieri GM; Holbert JM; Leventhal MR; Sebes JI
Am J Med Sci; 1999 Jul; 318(1):61-6. PubMed ID: 10408763
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
